Livne, O., Budney, A., Borodovsky, J., Shmulewitz, D., Walsh, C., Struble, C. A., Habib, M., Aharonovich, E., & Hasin, D. S. (2024). Age differences in patterns of cannabis use among an online US sample of adults who consume cannabis frequently. The American Journal of Drug and Alcohol Abuse, 50(2), 242–251. https://doi.org/10.1080/00952990.2024.2309340

Carter, E., Schatz, D., Isaacs, N., Garcia, J., Henry, B., Krawczyk, N., & Williams, A. R. (2024). Application of an opioid use disorder cascade of care in a large public health system. The American Journal of Drug and Alcohol Abuse, 50(2), 181–190. https://doi.org/10.1080/00952990.2024.2302500

McGuirt, A. F., & Brezing, C. A. (2024). Opioid-induced hypogonadism in opioid use disorder, its role in negative reinforcement, and implications for treatment and retention. The American Journal of Drug and Alcohol Abuse, 50(2), 132–138. https://doi.org/10.1080/00952990.2023.2292012

Borodovsky, J. T., Struble, C. A., Habib, M. I., Hasin, D. S., Shmulewitz, D., Walsh, C., Livne, O., Aharonovich, E., & Budney, A. J. (2023). Exploring survey methods for measuring consumption quantities of cannabis flower and concentrate products. The American Journal of Drug and Alcohol Abuse, 49(6), 733–745. https://doi.org/10.1080/00952990.2023.2246635

Mannes, Z. L., Livne, O., Knox, J., Hasin, D. S., & Kranzler, H. R. (2023). Prevalence and correlates of DSM-5 opioid withdrawal syndrome in U.S. adults with non-medical use of prescription opioids: results from a national sample. The American Journal of Drug and Alcohol Abuse, 49(6), 799–808. https://doi.org/10.1080/00952990.2023.2248646

Mariani, J. J., Basaraba, C., Pavlicova, M., Alschuler, D. M., Brooks, D. J., Mahony, A. L., Brezing, C., Naqvi, N. H., & Levin, F. R. (2023). Open label trial of lofexidine-assisted non-opioid induction onto naltrexone extended-release injection for opioid use disorder. The American Journal of Drug and Alcohol Abuse, 49(5), 618–629. https://doi.org/10.1080/00952990.2023.2241981

Chao, T., Todman, M., Foltin, R. W., Evans, S. M., & Bedi, G. (2023). Laboratory method to induce state boredom increases impulsive choice in people who use cocaine and controls. The American Journal of Drug and Alcohol Abuse, 50(1), 42–53. https://doi.org/10.1080/00952990.2023.2248544

Bunting, A. M., Shearer, R., Linden-Carmichael, A. N., Williams, A. R., Comer, S. D., Cerdá, M., & Lorvick, J. (2023). Are you thinking what I’m thinking? Defining what we mean by “polysubstance use.” The American Journal of Drug and Alcohol Abuse, 50(1), 1–7. https://doi.org/10.1080/00952990.2023.2248360

Williams, A. R., Aronowitz, S. V., Rowe, C., Gallagher, R., Behar, E., & Bisaga, A. (2023). Telehealth for opioid use disorder: retention as a function of demographics and rurality. The American Journal of Drug and Alcohol Abuse, 49(2), 260–265. https://doi.org/10.1080/00952990.2023.2180382

Jones, J. D., Rajachandran, L., Yocca, F., Risinger, R., De Vivo, M., Sabados, J., Levin, F. R., & Comer, S. D. (2023). Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial. The American Journal of Drug and Alcohol Abuse, 49(1), 109–122. https://doi.org/10.1080/00952990.2022.2144743

Oliva, A., Reed, S. C., Brooks, D. J., Levin, F. R., & Evans, S. M. (2022). Safety and tolerability of progesterone treatment for women with cocaine use disorder: a pilot treatment trial. The American Journal of Drug and Alcohol Abuse, 48(5), 586–595. https://doi.org/10.1080/00952990.2022.2114004